EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019–2023)

Helio S Sader iD, Mariana Castanheira, S J Ryan Arends, Timothy B Doyle

Antimicrobial Agents and Chemotherapy · 02.04.2025 · 69 (4)

DOI: 10.1128/aac.00124-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 02.04.2025. Verfasst von Helio S Sader und 3 weiteren Autor:innen. Beteiligte Einrichtung: Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA. Hauptthemen laut MEDLINE: Stenotrophomonas maltophilia, Anti-Bacterial Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of Stenotrophomonas maltophilia consecutively collected from United States medical centers in 2019–2023. Aztreonam-avibactam (MIC 50/90 , 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the most active compound, followed by trimethoprim-sulfamethoxazole (MIC 50/90 , ≤0.12/0.5 µg/mL; 96.9% susceptible), minocycline (MIC 50/90 , 0.5/2 µg/mL; 89.2% susceptible), and levofloxacin (MIC 50/90 , 1/8 µg/mL; 78.9% susceptible). Aztreonam-avibactam retained potent activity against isolates not susceptible to trimethoprim-sulfamethoxazole, minocycline, and/or levofloxacin (99.3%–100.0% inhibited at ≤8 µg/mL).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stenotrophomonas maltophiliaAnti-Bacterial AgentsMicrobial Sensitivity TestsUnited StatesHumansLevofloxacinTrimethoprim, Sulfamethoxazole Drug CombinationAztreonamMinocyclineGram-Negative Bacterial InfectionsAzabicyclo CompoundsDrug Resistance, Multiple, Bacterial

Stichwörter der Autor:innen

antimicrobial resistanceaztreonam-avibactambeta-lactamase inhibitor combinationhospital-acquired infectionminocyclinepneumonia

Substanzen

Anti-Bacterial AgentsLevofloxacinTrimethoprim, Sulfamethoxazole Drug CombinationAztreonamMinocyclineAzabicyclo Compoundsavibactam

Autor:innen und Institutionen

  • Element Iowa City (JMI Laboratories), North Liberty, Iowa, USA.

ORCID-Profile: Helio S Sader

Zitieren

APA

Sader, H. S., Castanheira, M., Arends, S. J. R., & Doyle, T. B. (2025). Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019–2023). Antimicrobial Agents and Chemotherapy, 69(4). https://doi.org/10.1128/aac.00124-25

Vancouver

Sader HS, Castanheira M, Arends SJR, Doyle TB. Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019–2023). Antimicrobial Agents and Chemotherapy. 2025;69(4). doi:10.1128/aac.00124-25

BibTeX
@article{Sader2025,
  author = {Sader, Helio S and Castanheira, Mariana and Arends, S J Ryan and Doyle, Timothy B},
  title = {Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019–2023)},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  volume = {69},
  number = {4},
  doi = {10.1128/aac.00124-25}
}
Kostenlos starten →